Journal of Medicinal Chemistry · 2019 · 48 citations · 24 references
MedicineOrthopaedic SurgeryPharmacologyCartilage RepairDrug DiscoveryMolecular PharmacologyArticular Cartilage StructureCartilage BreakdownCartilage DegenerationCartilage MetabolismIntra-articular TherapyOsteoarthritisArticular Cartilage LossCartilage Degradation MechanismsCartilage Extracellular MatrixCartilage Matrix HomeostasisChondrocyte Phenotype MaintenanceChondrogenic DifferentiationIn Vivo StudiesJoint Destruction
Osteoarthritis (OA) is a degenerative disease characterized by joint destruction and loss of cartilage. There are many unmet needs in the treatment of OA and there are few promising candidates for disease-modifying OA drugs, particularly, anabolic agents. Here, we describe the identification of novel quinazolin-4(3 H)-one derivatives, which stimulate chondrocyte cartilage matrix production via TRPV4 and mitigate damaged articular cartilage. We successfully identified the water-soluble, highly potent quinazolin-4(3 H)-one derivative 36 and studied its intra-articular physicochemical profile to use in in vivo surgical OA model studies. Compound 36·HCl provided relief from OA damage in a rat medial meniscal tear (MT) model. Specifically, 36·HCl dose-dependently suppressed cartilage degradation and enhanced the messenger RNA expression of aggrecan and SOX9 in cartilage isolated from MT-operated rat knees compared with knees treated with vehicle. These results suggest that 36 induces anabolic changes in articular cartilage and consequently reduces OA progression.
24
Sox9 is required for cartilage formation
Weimin Bi, Jian Min Deng, Zhaoping Zhang et al. · Nature Genetics · 1999 · 1.8K citations
Haruhiko Akiyama, Marie‐Christine Chaboissier, James F. Martin et al. · Genes & Development · 2002 · 1.7K citations · Full text